Canada - English - Health Canada

sanis health inc - ropinirole (ropinirole hydrochloride) - tablet - 1mg - ropinirole (ropinirole hydrochloride) 1mg - nonergot-derivative dopamine receptor agonists

Canada - English - Health Canada

sanis health inc - ropinirole (ropinirole hydrochloride) - tablet - 2mg - ropinirole (ropinirole hydrochloride) 2mg - nonergot-derivative dopamine receptor agonists

Canada - English - Health Canada

sanis health inc - ropinirole (ropinirole hydrochloride) - tablet - 5mg - ropinirole (ropinirole hydrochloride) 5mg - nonergot-derivative dopamine receptor agonists

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

actavis uk ltd - ropinirole hydrochloride - oral tablet - 500microgram

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

actavis uk ltd - ropinirole hydrochloride - oral tablet - 250microgram

United States - English - NLM (National Library of Medicine)

direct_rx - ropinirole hydrochloride (unii: d7zd41rzi9) (ropinirole - unii:030pyr8953) - 1.1 parkinson's disease ropinirole tablets are indicated for the treatment of parkinson’s disease. 1.2 restless legs syndrome ropinirole tablets are indicated for the treatment of moderate-to-severe primary restless legs syndrome (rls). ropinirole tablets are contraindicated in patients known to have a hypersensitivity/allergic reaction (including urticaria, angioedema, rash, pruritus) to ropinirole or to any of the excipients. 8.1 pregnancy risk summary there are no adequate data on the developmental risk associated with the use of ropinirole tablets in pregnant women. in animal studies, ropinirole had adverse effects on development when administered to pregnant rats at doses similar to (neurobehavioral impairment) or greater than (teratogenicity and embryolethality at >36 times) the maximum recommended human dose (mrhd) for parkinson’s disease. ropinirole doses associated with teratogenicity and embryolethality in pregnant rats were associated with maternal toxicity. in pregnant rabbits, ropinirole potentia

United States - English - NLM (National Library of Medicine)

west-ward pharmaceuticals corp. - ropinirole hydrochloride (unii: d7zd41rzi9) (ropinirole - unii:030pyr8953) - ropinirole 0.25 mg - ropinirole is indicated for the treatment of parkinson’s disease. ropinirole is indicated for the treatment of moderate-to-severe primary restless legs syndrome (rls). ropinirole tablets are contraindicated in patients known to have a hypersensitivity/allergic reaction (including urticaria, angioedema, rash, pruritus) to ropinirole or to any of the excipients. risk summary there are no adequate data on the developmental risk associated with the use of ropinirole in pregnant women. in animal studies, ropinirole had adverse effects on development when administered to pregnant rats at doses similar to (neurobehavioral impairment) or greater than (teratogenicity and embryolethality at >36 times) the maximum recommended human dose (mrhd) for parkinson’s disease. ropinirole doses associated with teratogenicity and embryolethality in pregnant rats were associated with maternal toxicity. in pregnant rabbits, ropinirole potentiated the teratogenic effects of l-dopa when these drugs were administered in combination [se

United States - English - NLM (National Library of Medicine)

carilion materials management - ropinirole hydrochloride (unii: d7zd41rzi9) (ropinirole - unii:030pyr8953) - ropinirole 1 mg - ropinirole tablets usp are indicated for the treatment of parkinson’s disease. ropinirole tablets usp are indicated for the treatment of moderate-to-severe primary restless legs syndrome (rls). ropinirole tablets usp are contraindicated in patients known to have hypersensitivity/allergic reaction (including urticaria, angioedema, rash, pruritus) to ropinirole or to any of the excipients. pregnancy category c. there are no adequate and well-controlled studies in pregnant women. in animal reproduction studies, ropinirole has been shown to have adverse effects on embryo-fetal development, including teratogenic effects. ropinirole should be used during pregnancy only if the potential benefit outweighs the potential risk to the fetus. oral treatment of pregnant rats with ropinirole during organogenesis resulted in decreased fetal body weight, increased fetal death, and digital malformations at 24, 36, and 60 times, respectively, the maximum recommended human dose (mrhd) for parkinson’s disease (24 mg/day) on a mg

United States - English - NLM (National Library of Medicine)

bryant ranch prepack - ropinirole hydrochloride (unii: d7zd41rzi9) (ropinirole - unii:030pyr8953) - ropinirole 0.5 mg - ropinirole tablets are indicated for the treatment of parkinson’s disease. ropinirole tablets are indicated for the treatment of moderate-to-severe primary restless legs syndrome (rls). ropinirole is contraindicated in patients known to have a hypersensitivity/allergic reaction (including urticaria, angioedema, rash, pruritus) to ropinirole or to any of the excipients. risk summary there are no adequate data on the developmental risk associated with the use of ropinirole in pregnant women. in animal studies, ropinirole had adverse effects on development when administered to pregnant rats at doses similar to (neurobehavioral impairment) or greater than (teratogenicity and embryolethality at >36 times) the maximum recommended human dose (mrhd) for parkinson’s disease. ropinirole doses associated with teratogenicity and embryolethality in pregnant rats were associated with maternal toxicity. in pregnant rabbits, ropinirole potentiated the teratogenic effects of l-dopa when these drugs were administered in combin

United States - English - NLM (National Library of Medicine)

unit dose services - ropinirole hydrochloride (unii: d7zd41rzi9) (ropinirole - unii:030pyr8953) - ropinirole 1 mg - ropinirole tablets are indicated for the treatment of parkinson’s disease. ropinirole tablets are indicated for the treatment of moderate-to-severe primary restless legs syndrome (rls). ropinirole is contraindicated in patients known to have a hypersensitivity/allergic reaction (including urticaria, angioedema, rash, pruritus) to ropinirole or to any of the excipients. risk summary there are no adequate data on the developmental risk associated with the use of ropinirole in pregnant women. in animal studies, ropinirole had adverse effects on development when administered to pregnant rats at doses similar to (neurobehavioral impairment) or greater than (teratogenicity and embryolethality at >36 times) the maximum recommended human dose (mrhd) for parkinson’s disease. ropinirole doses associated with teratogenicity and embryolethality in pregnant rats were associated with maternal toxicity. in pregnant rabbits, ropinirole potentiated the teratogenic effects of l-dopa when these drugs were administered in combin